We can't find the internet
Attempting to reconnect
19305.1 PFLS-LS
Investigation of in vitro response of human blood to Qvanteq's anti-thrombotic and pro-healing surface technology applied on vascular stents
Zusammenfassung
Investigation of in vitro response of human blood to Qvanteq's anti-thrombotic and pro-healing surface technology applied on vascular stents
Weitere Texte
Abstract
Qvanteq AG (Zurich, Switzerland; ETH Spinoff) has developped a proprietary coating-free surface technology for vascular stents (small metal mesh tubes, implanted into blood vessels to restore blood flow). The anti-thrombotic properties of a surface-treated stent promisses clinical advantages for patients and healthcare payers as it potentially reduces magnitude and duration of post-intervention anti-coagulant drug therapies and cumbersome re-interventions
Beteiligte
Arik Zucker
Wirtschaftspartner
arik.zucker@qvanteq.com
Qvanteq AG Arik Zucker Technoparkstrasse 1 8005 Zürich ZH CH
Martin Ehrbar
Kontaktperson
martin.ehrbar@usz.ch
USZ Universitätsspital Zürich Martin Ehrbar Schmelzbergstrasse 12 8091 Zürich ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2016-07-31
- Enddatum
- 2018-04-30
- Bewilligte Gesamtkosten
- CHF 295638.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T115 Medical technology 100.0%